Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Fierce Pharma
Merck grows more ambitious about 'workhorse' TROP2 ADC
Merck has already registered 15 global phase 3 trials for its Kelun-partnered TROP2 antibody-drug conjugate, sac-TMT.
Angus Liuu
Oct 20, 2025 4:00pm
ESMO: Daiichi, Merck move ovarian cancer ADC toward pivotal test
Oct 20, 2025 10:45am
GSK says 'stay tuned' for more ADC data as Hansoh posts 49% ORR
Oct 19, 2025 10:40am
ESMO: Tubulis' next-gen ADC lives up to hype with 59% ORR
Oct 19, 2025 4:15am
Hansoh, Chugai ink separate and lucrative licensing agreements
Oct 17, 2025 11:04am
Boehringer digs in on ADCs with $991M AimedBio licensing accord
Oct 15, 2025 10:05am
